Tripathi Shashwat, Vivas-Buitrago Tito, Domingo Ricardo A, Biase Gaetano De, Brown Desmond, Akinduro Oluwaseun O, Ramos-Fresnedo Andres, Sherman Wendy, Gupta Vivek, Middlebrooks Erik H, Sabsevitz David S, Porter Alyx B, Uhm Joon H, Bendok Bernard R, Parney Ian, Meyer Fredric B, Chaichana Kaisorn L, Swanson Kristin R, Quiñones-Hinojosa Alfredo
1Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida.
10Feinberg School of Medicine, Northwestern University, Chicago, Illinois; and.
J Neurosurg. 2021 Oct 29;136(6):1567-1575. doi: 10.3171/2021.6.JNS21925. Print 2022 Jun 1.
Recent studies have proposed resection of the T2 FLAIR hyperintensity beyond the T1 contrast enhancement (supramarginal resection [SMR]) for IDH-wild-type glioblastoma (GBM) to further improve patients' overall survival (OS). GBMs have significant variability in tumor cell density, distribution, and infiltration. Advanced mathematical models based on patient-specific radiographic features have provided new insights into GBM growth kinetics on two important parameters of tumor aggressiveness: proliferation rate (ρ) and diffusion rate (D). The aim of this study was to investigate OS of patients with IDH-wild-type GBM who underwent SMR based on a mathematical model of cell distribution and infiltration profile (tumor invasiveness profile).
Volumetric measurements were obtained from the selected regions of interest from pre- and postoperative MRI studies of included patients. The tumor invasiveness profile (proliferation/diffusion [ρ/D] ratio) was calculated using the following formula: ρ/D ratio = (4π/3)2/3 × (6.106/[VT21/1 - VT11/1])2, where VT2 and VT1 are the preoperative FLAIR and contrast-enhancing volumes, respectively. Patients were split into subgroups based on their tumor invasiveness profiles. In this analysis, tumors were classified as nodular, moderately diffuse, or highly diffuse.
A total of 101 patients were included. Tumors were classified as nodular (n = 34), moderately diffuse (n = 34), and highly diffuse (n = 33). On multivariate analysis, increasing SMR had a significant positive correlation with OS for moderately and highly diffuse tumors (HR 0.99, 95% CI 0.98-0.99; p = 0.02; and HR 0.98, 95% CI 0.96-0.99; p = 0.04, respectively). On threshold analysis, OS benefit was seen with SMR from 10% to 29%, 10% to 59%, and 30% to 90%, for nodular, moderately diffuse, and highly diffuse, respectively.
The impact of SMR on OS for patients with IDH-wild-type GBM is influenced by the degree of tumor invasiveness. The authors' results show that increasing SMR is associated with increased OS in patients with moderate and highly diffuse IDH-wild-type GBMs. When grouping SMR into 10% intervals, this benefit was seen for all tumor subgroups, although for nodular tumors, the maximum beneficial SMR percentage was considerably lower than in moderate and highly diffuse tumors.
近期研究提出,对于异柠檬酸脱氢酶(IDH)野生型胶质母细胞瘤(GBM),切除超出T1加权像对比增强范围的T2液体衰减反转恢复序列(FLAIR)高信号区域(即边缘上切除[SMR]),以进一步提高患者的总生存期(OS)。GBM在肿瘤细胞密度、分布和浸润方面存在显著差异。基于患者特异性影像学特征的先进数学模型,在肿瘤侵袭性的两个重要参数——增殖率(ρ)和扩散率(D)方面,为GBM生长动力学提供了新的见解。本研究的目的是基于细胞分布和浸润情况的数学模型(肿瘤侵袭性情况),调查接受SMR的IDH野生型GBM患者的OS。
从纳入患者术前和术后MRI研究的选定感兴趣区域获取体积测量值。使用以下公式计算肿瘤侵袭性情况(增殖/扩散[ρ/D]比值):ρ/D比值 = (4π/3)2/3 × (6.106/[VT21/1 - VT11/1])2,其中VT2和VT1分别是术前FLAIR和对比增强体积。根据患者的肿瘤侵袭性情况将其分为亚组。在本分析中,肿瘤被分类为结节状、中度弥漫性或高度弥漫性。
共纳入101例患者。肿瘤被分类为结节状(n = 34)、中度弥漫性(n = 34)和高度弥漫性(n = 33)。在多变量分析中,对于中度和高度弥漫性肿瘤,增加SMR与OS呈显著正相关(风险比[HR] 0.99,95%置信区间[CI] 0.98 - 0.99;p = 0.02;以及HR 0.98,95% CI 0.96 - 0.99;p = 0.04)。在阈值分析中,对于结节状、中度弥漫性和高度弥漫性肿瘤,分别在SMR为10%至29%、10%至59%和30%至90%时观察到OS获益。
SMR对IDH野生型GBM患者OS的影响受肿瘤侵袭程度的影响。作者的结果表明,在中度和高度弥漫性IDH野生型GBM患者中,增加SMR与OS增加相关。当将SMR按10%的间隔分组时,所有肿瘤亚组均观察到这种获益,尽管对于结节状肿瘤,最大有益SMR百分比远低于中度和高度弥漫性肿瘤。